RESUMEN
Biomarkers of transplant tolerance would enhance the safety and feasibility of clinical tolerance trials and potentially facilitate management of patients receiving immunosuppression. To this end, we examined blood from spontaneously tolerant renal transplant recipients and patients enrolled in two interventional tolerance trials using flow cytometry and gene expression profiling. Using a previously reported tolerant cohort as well as newly identified tolerant patients, we confirmed our previous finding that tolerance was associated with increased expression of B cell-associated genes relative to immunosuppressed patients. This was not accounted for merely by an increase in total B cell numbers, but was associated with the increased frequencies of transitional and naïve B cells. Moreover, serial measurements of gene expression demonstrated that this pattern persisted over several years, although patients receiving immunosuppression also displayed an increase in the two most dominant tolerance-related B cell genes, IGKV1D-13 and IGLL-1, over time. Importantly, patients rendered tolerant via induction of transient mixed chimerism, and those weaned to minimal immunosuppression, showed similar increases in IGKV1D-13 as did spontaneously tolerant individuals. Collectively, these findings support the notion that alterations in B cells may be a common theme for tolerant kidney transplant recipients, and that it is a useful monitoring tool in prospective trials.
Asunto(s)
Factor Activador de Células B/genética , Regulación de la Expresión Génica , Memoria Inmunológica/genética , Trasplante de Riñón/efectos adversos , Tolerancia al Trasplante/genética , Adulto , Aloinjertos , Linfocitos B/inmunología , Femenino , Citometría de Flujo , Perfilación de la Expresión Génica , Rechazo de Injerto/genética , Supervivencia de Injerto/genética , Humanos , Trasplante de Riñón/métodos , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Pronóstico , Sistema de Registros , Medición de Riesgo , Receptores de Trasplantes , Inmunología del Trasplante/genética , Tolerancia al Trasplante/inmunología , Resultado del TratamientoRESUMEN
Posttransplantation lymphoproliferative disorder (PTLD) is an important complication of transplantation. Risk factors include increased overall immunosuppression exposure and inadequate antiviral prophylaxis; however, the effects of T-cell-depleting agents on PTLD are unclear. A systematic literature review was conducted to assess PTLD in clinical studies published 1999-2009 in transplant patients with ≥ 3 years follow-up who received Thymoglobulin for induction. Twenty studies were identified (12 kidney, 7 heart, and 1 liver), of which 3 were excluded for insufficient PTLD reporting. The final study group comprised 2,246 kidney and heart transplant recipients (liver study excluded) who received Thymoglobulin. At a median follow-up of 5 years, the incidence of PTLD was 0.98% (kidney, 0.93%; heart, 1.05%) among Thymoglobulin-treated patients. The cumulative Thymoglobulin dose reported in these studies was not associated with the development of PTLD (P = NS). However, incidence of PTLD was significantly lower with antiviral prophylaxis (0.63%) than without (1.87%; P = .013). Heart transplant recipients not receiving antiviral prophylaxis had the highest PTLD incidence, possibly attributable to a greater overall immunosuppressive burden. This analysis revealed that PTLD incidences in kidney and heart transplant recipients receiving Thymoglobulin were low overall and perhaps related more to concomitant anti-viral prophylaxis use.
Asunto(s)
Suero Antilinfocítico/administración & dosificación , Trasplante de Corazón/efectos adversos , Trasplante de Riñón/efectos adversos , Trastornos Linfoproliferativos/etiología , HumanosRESUMEN
Current immunosuppressive regimens in renal transplantation typically include calcineurin inhibitors (CNIs) and corticosteroids, both of which have toxicities that can impair recipient and allograft health. This 1-year, randomized, controlled, open-label, exploratory study assessed two belatacept-based regimens compared to a tacrolimus (TAC)-based, steroid-avoiding regimen. Recipients of living and deceased donor renal allografts were randomized 1:1:1 to receive belatacept-mycophenolate mofetil (MMF), belatacept-sirolimus (SRL), or TAC-MMF. All patients received induction with 4 doses of Thymoglobulin (6 mg/kg maximum) and an associated short course of corticosteroids. Eighty-nine patients were randomized and transplanted. Acute rejection occurred in 4, 1 and 1 patient in the belatacept-MMF, belatacept-SRL and TAC-MMF groups, respectively, by Month 6; most acute rejection occurred in the first 3 months. More than two-thirds of patients in the belatacept groups remained on CNI- and steroid-free regimens at 12 months and the calculated glomerular filtration rate was 8-10 mL/min higher with either belatacept regimen than with TAC-MMF. Overall safety was comparable between groups. In conclusion, primary immunosuppression with belatacept may enable the simultaneous avoidance of both CNIs and corticosteroids in recipients of living and deceased standard criteria donor kidneys, with acceptable rates of acute rejection and improved renal function relative to a TAC-based regimen.
Asunto(s)
Inmunoconjugados/uso terapéutico , Terapia de Inmunosupresión/métodos , Abatacept , Corticoesteroides/efectos adversos , Adulto , Inhibidores de la Calcineurina , Femenino , Rechazo de Injerto , Supervivencia de Injerto/efectos de los fármacos , Humanos , Inmunoconjugados/efectos adversos , Terapia de Inmunosupresión/efectos adversos , Riñón/fisiología , Trasplante de Riñón , Masculino , Persona de Mediana Edad , Ácido Micofenólico/análogos & derivados , Ácido Micofenólico/uso terapéutico , Sirolimus/uso terapéutico , Tacrolimus/uso terapéuticoRESUMEN
Continued progress in organ donation will help enable transplantation to alleviate the increasing incidence of end-stage organ disease. This article discusses the implementation and effect of the federally initiated Organ Donation Breakthrough Collaborative; it then reviews organ donation data, living and deceased, from 1995 to 2004. It is the first annual report of the Scientific Registry of Transplant Recipients to include national data following initiation of the collaborative in 2003. Prior to that, annual growth in deceased donation was 2%-4%; in 2004, after initiation of the collaborative, deceased donation increased 11%. Identification and dissemination of best practices for organ donation have emphasized new strategies for improved consent, including revised approaches to minority participation, timing of requests and team design. The number of organs recovered from donation after cardiac death (DCD) grew from 64 in 1995 to 391 in 2004. While efforts are ongoing to develop methodologies for identifying expanded criteria donors (ECD) for organs other than kidney, it is clear DCD and ECD raise questions regarding cost and recovery. The number of living donor organs increased from 3493 in 1995 to 7002 in 2004; data show trends toward more living unrelated donors and those providing non-directed donations.
Asunto(s)
Donadores Vivos/estadística & datos numéricos , Trasplante de Órganos/historia , Trasplante de Órganos/estadística & datos numéricos , Obtención de Tejidos y Órganos/historia , Obtención de Tejidos y Órganos/estadística & datos numéricos , Etnicidad , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Trasplante de Órganos/tendencias , Donantes de Tejidos , Recolección de Tejidos y Órganos/métodos , Recolección de Tejidos y Órganos/estadística & datos numéricos , Obtención de Tejidos y Órganos/tendencias , Estados UnidosRESUMEN
A national conference on organ donation after cardiac death (DCD) was convened to expand the practice of DCD in the continuum of quality end-of-life care. This national conference affirmed the ethical propriety of DCD as not violating the dead donor rule. Further, by new developments not previously reported, the conference resolved controversy regarding the period of circulatory cessation that determines death and allows administration of pre-recovery pharmacologic agents, it established conditions of DCD eligibility, it presented current data regarding the successful transplantation of organs from DCD, it proposed a new framework of data reporting regarding ischemic events, it made specific recommendations to agencies and organizations to remove barriers to DCD, it brought guidance regarding organ allocation and the process of informed consent and it set an action plan to address media issues. When a consensual decision is made to withdraw life support by the attending physician and patient or by the attending physician and a family member or surrogate (particularly in an intensive care unit), a routine opportunity for DCD should be available to honor the deceased donor's wishes in every donor service area (DSA) of the United States.
Asunto(s)
Muerte Súbita Cardíaca , Obtención de Tejidos y Órganos/ética , Adolescente , Adulto , Niño , Humanos , Trasplante de Hígado/mortalidad , Trasplante de Hígado/estadística & datos numéricos , Persona de Mediana Edad , Selección de PacienteRESUMEN
BACKGROUND: Cardiopulmonary bypass (CPB) is associated with poorly understood alterations in gastrointestinal (GI) perfusion. Intestinal fatty acid binding protein (IFABP), a cytosolic protein uniquely located in mature small-intestinal enterocytes, has been shown to be a sensitive biochemical marker of early intestinal ischemia when assayed in urine. We hypothesized that if significant small-intestinal ischemia occurs with CPB, then urine IFABP levels should be concomitantly elevated. METHODS: Twenty-nine patients (15 low risk and 14 high risk) undergoing cardiac surgery with CPB were studied prospectively. Serial urine IFABP levels were measured and results were correlated with clinical outcomes. RESULTS: None of the low-risk patients had IFABP elevations or experienced GI complications. Five of the high-risk patients had IFABP elevations, and three of the five developed GI complications. Within the high-risk cohort, the only significant difference between patients with or without IFABP elevations was the GI complication rate (P = 0.03). Overall, patients with IFABP elevations had a significantly higher mean ASA class and significant increases in mean CPB and aortic cross-clamp times, mean time to oral intake, median ICU and postoperative lengths of stay, and GI complications. CONCLUSIONS: In low-risk bypass patients, small-bowel mucosal perfusion appeared to be maintained, while in the high-risk population, 21% of the patients sustained clinically significant mucosal compromise. In this pilot study, urine IFABP was 100% sensitive and 92% specific with respect to GI complications. Since elevated urine IFABP concentrations appeared to correlate with clinical GI complications, urine IFABP may be a useful marker to identify the patient at risk for postbypass GI complications.
Asunto(s)
Puente Cardiopulmonar , Proteínas Portadoras/orina , Isquemia/metabolismo , Proteínas de Neoplasias , Complicaciones Posoperatorias/metabolismo , Proteínas Supresoras de Tumor , Anciano , Proteína de Unión a los Ácidos Grasos 7 , Proteínas de Unión a Ácidos Grasos , Femenino , Humanos , Mucosa Intestinal/metabolismo , Intestinos/irrigación sanguínea , Masculino , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Estudios ProspectivosRESUMEN
INTRODUCTION: The enterocyte-specific protein, intestinal fatty acid binding protein (I-FABP), is detectable in serum only after intestinal injury. Previous studies in animals suggest that I-FABP might be a useful marker of intestinal allograft rejection. MATERIALS AND METHODS: I-FABP was repetitively measured in nine intestinal transplant recipients and correlated with findings of surveillance endoscopy. RESULTS: Average interval between I-FABP determination and biopsy was 3.4 days (SD=4.2 days). Average number of rejection episodes per patient totalled 1.6+/-1.2. General linear modeling demonstrated no tendency for increases in serum FABP to precede histologic graft rejection (P=0.263). Restriction of the analysis to I-FABP determinations 1 day before or on the day of biopsy failed to affect these results. Minor increases in I-FABP were often associated with histologically normal grafts, whereas rejection often occurred when I-FABP was not detectable. DISCUSSION: Serum I-FABP levels do not predict clinical intestinal allograft rejection.
Asunto(s)
Proteínas Portadoras/sangre , Rechazo de Injerto/diagnóstico , Intestinos/trasplante , Proteínas de Neoplasias , Trasplante Homólogo/fisiología , Proteínas Supresoras de Tumor , Adulto , Biomarcadores/sangre , Biomarcadores/orina , Proteínas Portadoras/orina , Niño , Preescolar , Proteína de Unión a los Ácidos Grasos 7 , Proteínas de Unión a Ácidos Grasos , Ácidos Grasos/metabolismo , Rechazo de Injerto/sangre , Rechazo de Injerto/patología , Humanos , Intestinos/patología , Monitoreo Fisiológico/métodos , Reproducibilidad de los Resultados , Trasplante Homólogo/patologíaAsunto(s)
Citocinas/sangre , Interleucinas/sangre , Mucosa Intestinal/trasplante , Intestinos/trasplante , Proteínas de Neoplasias , Daño por Reperfusión/inmunología , Trasplante Isogénico/inmunología , Proteínas Supresoras de Tumor , Biomarcadores/sangre , Proteínas Portadoras/análisis , Supervivencia Celular , Proteína de Unión a los Ácidos Grasos 7 , Proteínas de Unión a Ácidos Grasos , Ácidos Grasos/metabolismo , Humanos , Técnicas para Inmunoenzimas , Interleucina-6/sangre , Interleucina-8/sangre , Mucosa Intestinal/irrigación sanguínea , Mucosa Intestinal/inmunología , Intestinos/irrigación sanguínea , Intestinos/inmunología , Proteína P2 de Mielina/análisis , Sensibilidad y Especificidad , Trasplante Isogénico/patología , Factor de Necrosis Tumoral alfa/análisisRESUMEN
OBJECTIVE: To study the effect of warm ischemia and reperfusion (I/R) on local perfusion and leukocyte-vessel wall interactions in vivo in all small bowel layers, and to quantify small bowel tissue injury histologically and by measuring intestinal fatty acid binding protein (I-FABP) release from the enterocytes. SUMMARY BACKGROUND DATA: Gut injury as a result of I/R plays a pivotal role in a variety of clinical conditions, such as small bowel transplantation, heart or aortic surgery, and (septic) shock. The precise mechanism behind I/R injury and the role of microvascular changes remain unclear. The influence of warm I/R of the gut on microvascular parameters in the different gut layers has not been studied before. METHODS: Anesthetized Lewis rats were either subjected to 30 minutes of ischemia and 1 hour of reperfusion or sham-treated as controls. After ligating the inferior mesenteric artery, total warm ischemia was induced by clamping the superior mesenteric artery. Intravital video microscopic measurements were obtained at intervals. Tissue injury of the small bowel and other organs was histologically evaluated afterward. In addition, plasma levels of I-FABP were determined to measure enterocyte damage. RESULTS: After ischemia, mean red blood cell velocity decreased significantly in all layers of the small bowel, but no diameter changes were observed. Leukocyte-vessel wall interactions increased in the submucosa but not in the muscle layers. Plasma levels of I-FABP significantly increased from 30 minutes of reperfusion onward. The intestinal mucosa was severely injured; no histologic damage was detected in other tissues. CONCLUSIONS: This is the first in vivo study showing that total warm ischemia of the rat gut impairs perfusion in the whole small bowel, whereas leukocyte-vessel wall interactions increase in the submucosal layer only. Therefore, the early inflammatory response to I/R seems to be limited to the submucosa. Both microvascular effects may have contributed to the severe morphologic and functional mucosal injury observed after I/R.
Asunto(s)
Proteínas Portadoras/metabolismo , Mucosa Intestinal/irrigación sanguínea , Intestino Delgado/irrigación sanguínea , Leucocitos/inmunología , Proteína P2 de Mielina/metabolismo , Proteínas de Neoplasias , Proteínas del Tejido Nervioso , Daño por Reperfusión/inmunología , Animales , Biomarcadores , Velocidad del Flujo Sanguíneo/fisiología , Permeabilidad de la Membrana Celular/inmunología , Proteína de Unión a los Ácidos Grasos 7 , Proteínas de Unión a Ácidos Grasos , Mucosa Intestinal/inmunología , Mucosa Intestinal/patología , Intestino Delgado/patología , Leucocitos/patología , Masculino , Microcirculación/patología , Ratas , Ratas Endogámicas Lew , Daño por Reperfusión/patologíaRESUMEN
BACKGROUND/PURPOSE: Intestinal fatty acid-binding protein (IFABP) is found within cells at the tip of the intestinal villi, an area commonly injured when necrotizing enterocolitis (NEC) occurs. This study was undertaken to determine if measuring IFABP concentrations in the bloodstream early in the course of NEC would differentiate patients by severity before clinical findings made it clear who had stage 3 NEC and who had milder stages. METHODS: Three plasma samples from newborn infants evaluated for NEC were obtained at symptom onset and after 8 and 24 hours. IFABP concentration was measured by radioimmunoassay. Infants were classified by the final and most severe stage of NEC, and IFABP levels were compared between groups at each sampling. RESULTS: IFABP was detectable in blood samples from all 7 infants with stage 3 NEC compared with 3 of 24 with stages 1 or 2 NEC. Elevated plasma IFABP concentrations were detectable before clinical staging could be made in 5 of the 7 subjects with stage 3 NEC. CONCLUSION: IFABP may be a specific marker for early identification of severe NEC.
Asunto(s)
Proteínas Portadoras/sangre , Enterocolitis Necrotizante/sangre , Ácidos Grasos/sangre , Intestino Delgado/metabolismo , Proteína P2 de Mielina/sangre , Proteínas de Neoplasias , Proteínas Supresoras de Tumor , Biomarcadores/sangre , Proteína de Unión a los Ácidos Grasos 7 , Proteínas de Unión a Ácidos Grasos , Humanos , Recién Nacido , Proyectos Piloto , Sensibilidad y Especificidad , Índice de Severidad de la EnfermedadRESUMEN
This was a prospective study designed to evaluate the extent to which intestinal mucosal compromise occurs in adult critical care patients with and without systemic inflammatory response syndrome (SIRS) and to correlate the degree of intestinal injury with outcome. Ten patients from a university hospital surgical intensive care unit were identified who manifested SIRS at the time of admission to the intensive care unit. Five other critical care patients without SIRS were also evaluated. The Acute Physiology and Chronic Health Evaluation II score was determined. Intestinal mucosal viability was assessed by serial measurement of serum and urine iFABP intestinal fatty acid binding protein (iFABP), a sensitive and specific marker for mucosal injury. Outcome in terms of the development of multiorgan dysfunction syndrome, adult respiratory distress syndrome, and survival was determined. iFABP was detectable in the serum or urine in 8 out of 10 patients with SIRS. Among the 4 patients with detectable serum iFABP, 2 died and 1 developed severe adult respiratory distress syndrome. Nine of 11 patients without detectable serum iFABP recovered without major morbidity. iFABP was detectable in most patients with SIRS, suggesting that subclinical intestinal mucosal compromise is a frequent component of this syndrome. When iFABP was detectable, particularly in the serum, the prognosis was poor, even in the absence of SIRS, indicating that iFABP may be a relevant and independent predictor of outcome in critical care patients.
Asunto(s)
Mucosa Intestinal/irrigación sanguínea , Isquemia/etiología , Proteínas de Neoplasias , Síndrome de Respuesta Inflamatoria Sistémica/fisiopatología , Proteínas Supresoras de Tumor , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Proteínas Portadoras/sangre , Proteínas Portadoras/orina , Enfermedad Crítica , Proteína de Unión a los Ácidos Grasos 7 , Proteínas de Unión a Ácidos Grasos , Ácidos Grasos/sangre , Ácidos Grasos/orina , Femenino , Humanos , Mucosa Intestinal/metabolismo , Masculino , Persona de Mediana Edad , Proteína P2 de Mielina/sangre , Proteína P2 de Mielina/orina , Estudios Prospectivos , Índice de Severidad de la Enfermedad , Síndrome de Respuesta Inflamatoria Sistémica/sangre , Síndrome de Respuesta Inflamatoria Sistémica/orinaRESUMEN
BACKGROUND: Intestinal mucosal ischemia and subsequent barrier dysfunction have been related to the development of organ dysfunction and death in the critically ill. We hypothesized that urine concentrations of intestinal fatty acid binding protein (IFABP), a sensitive marker of intestinal ischemia, might predict the development of the systemic inflammatory response syndrome (SIRS) and organ dysfunction. METHODS: One hundred consecutive critically ill patients were prospectively studied for the development of infectious complications, organ dysfunction, and SIRS. Urine was collected daily for measurement of IFABP. RESULTS: A total of 58 males and 42 females (mean age, 56 years; range,16-85 years) were studied. Of these 100 patients, 40 patients developed complications and 5 patients developed SIRS. IFABP was significantly elevated in all patients with SIRS, and IFABP levels peaked an average of 1.4 days (range, 0-7 days) before the diagnosis of SIRS. CONCLUSION: Elevated concentrations of urine IFABP correlated with the clinical development of SIRS. Studies to assess the utility of IFABP as a predictor of organ dysfunction and SIRS in the critically ill are warranted.
Asunto(s)
Proteínas Portadoras/orina , Infecciones/orina , Insuficiencia Multiorgánica/orina , Proteína P2 de Mielina/orina , Proteínas de Neoplasias , Síndrome de Respuesta Inflamatoria Sistémica/orina , Proteínas Supresoras de Tumor , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Biomarcadores/orina , Cuidados Críticos , Proteína de Unión a los Ácidos Grasos 7 , Proteínas de Unión a Ácidos Grasos , Femenino , Estudios de Seguimiento , Humanos , Mucosa Intestinal/irrigación sanguínea , Isquemia/orina , Masculino , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Reproducibilidad de los Resultados , Factores de TiempoRESUMEN
BACKGROUND: Human intestinal fatty acid binding protein (hIFABP) is a cytoplasmic protein of mature small intestinal epithelium. Work with the rat demonstrated that serum levels of IFABP correlated with early phases of intestinal mucosal injury. The aim of this study was to develop an assay for hIFABP and assess its usefulness as a marker for intestinal mucosal injury in human beings. METHODS: Recombinant hIFABP (r-hIFABP) was used to produce rabbit anti-hIFABP. Specificity and avidity of binding were tested with immunoprecipitation and Scatchard analysis. r-hIFABP was labeled with 125I, and a competitive assay was developed. Urine and serum from normal volunteers and from patients with necrotizing enterocolitis (NEC), acute thromboembolic related intestinal ischemia, and systemic inflammatory response syndrome were tested for hIFABP. RESULTS: Molecular weight was 10(-12) kd, limit of detection was 1.87 ng/ml, and no cross-reactivity occurred when tested against rat IFABP or human heart FABP. Mean levels of hIFABP (ng/ml) were controls (serum less than 1.87, urine less than 1.87), NEC (serum 14.7 ng/ml), intestinal ischemia (serum 50 ng/ml, urine 52.3 ng/ml), systemic inflammatory response syndrome (serum 5.3 ng/ml, urine 13.2 ng/ml). CONCLUSIONS: This assay is quantitative for hIFABP in serum and urine. Results from both normal persons and those with various causes of intestinal ischemia parallel our previous findings in the rat. Preliminary findings suggest that hIFABP may serve as a diagnostic marker for early intestinal mucosal compromise and, in addition, that it should prove useful as a tool in developing rationale therapeutic regimens to treat these complex clinical problems.
Asunto(s)
Proteínas Portadoras/metabolismo , Colitis Isquémica/metabolismo , Intestino Delgado/metabolismo , Proteína P2 de Mielina/metabolismo , Proteínas de Neoplasias , Proteínas del Tejido Nervioso , Proteínas Supresoras de Tumor , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Animales , Especificidad de Anticuerpos , Unión Competitiva/fisiología , Líquidos Corporales/química , Proteínas Portadoras/análisis , Proteínas Portadoras/inmunología , Proteína de Unión a los Ácidos Grasos 7 , Proteínas de Unión a Ácidos Grasos , Ácidos Grasos/metabolismo , Femenino , Humanos , Inmunoelectroforesis , Intestino Delgado/irrigación sanguínea , Intestino Delgado/química , Radioisótopos de Yodo , Masculino , Persona de Mediana Edad , Proteína P2 de Mielina/análisis , Proteína P2 de Mielina/inmunología , Conejos , Radioinmunoensayo , Ratas , Proteínas RecombinantesAsunto(s)
Amilasas/sangre , Creatinina/sangre , Rechazo de Injerto/diagnóstico , Trasplante de Riñón/fisiología , Trasplante de Páncreas/fisiología , Pancreatitis/diagnóstico , Complicaciones Posoperatorias/diagnóstico , Tripsinógeno/sangre , Enfermedad Aguda , Amilasas/orina , Biomarcadores/sangre , Biomarcadores/orina , Diagnóstico Diferencial , Rechazo de Injerto/sangre , Humanos , Trasplante de Riñón/inmunología , Monitoreo Fisiológico , Trasplante de Páncreas/inmunología , Pancreatitis/sangre , Trasplante HomólogoAsunto(s)
Suero Antilinfocítico/uso terapéutico , Rechazo de Injerto/prevención & control , Inmunosupresores/uso terapéutico , Trasplante de Riñón/inmunología , Ácido Micofenólico/análogos & derivados , Adolescente , Adulto , Azatioprina/uso terapéutico , Biopsia , Cadáver , Femenino , Rechazo de Injerto/epidemiología , Rechazo de Injerto/patología , Humanos , Terapia de Inmunosupresión/métodos , Incidencia , Trasplante de Riñón/patología , Masculino , Ácido Micofenólico/uso terapéutico , Donantes de Tejidos , Trasplante HomólogoRESUMEN
Hepatic tissue concentrations of FK506 have been correlated with early acute rejection following liver transplantation. Asialoglycoproteins (AGP) reputedly bind FK506 in blood. AGP are removed from the circulation by the liver via the AGP receptor (AGPr), which resides on hepatocytes. This study was undertaken to determine if the AGP-AGPr mechanism enhances the delivery of FK506 to hepatocytes. Human orosomucoid (OM) was used as a representative AGP. asialoOM (aOM) was prepared by desialation of OM. Fresh rat hepatocytes were isolated by collagenase digestion. Tritium labeled FK506 (FK) was used to identify and quantitate FK506. Quantitation of FK in serum and culture media was by direct counting. FK in animal tissues used a method developed in our laboratory for the purpose. AGPr on resting hepatocytes was demonstrated by flow cytometry using FITC-orosomucoid and FITC-BSA controls. AGPr were enhanced by 2 g glucose/L. Two serum FK-binding fractions, 44 kD and 15 kD, were identified by gel filtration. Exogenous OM avidly bound FK and displaced FK activity from the 15 kD fraction. Serum (1%) and the 44 kD fraction enhanced the uptake of FK by hepatocytes, while serum depleted of OM-aOM by affinity chromatography was only 72.5% as effective as control serum; aOM enhanced the uptake of FK by hepatocytes to a degree similar to that of control serum but OM did not significantly affect the uptake of FK. Cold FK506 blocked the uptake and was dose dependent; cold CsA had no effect. Affinity extraction of OM from serum to which FK had previously been added removed 28.4% of FK activity. Following i.v. infusion, the kidney had the highest and liver the lowest tissue concentration of FK at 1 hr and 3 hr. In contrast, after oral administration the liver had the highest concentrations of the other tissues tested. The AGP-AGPr mechanism plays a significant role in the delivery of FK506 to hepatocytes and is likely responsible for the differences in bioavailability observed after oral and i.v. administration. Factors governing the AGP-AGPr mechanism are germane to understanding both the efficacy and toxicity of FK506 and the development optimal therapeutic strategies.
Asunto(s)
Asialoglicoproteínas/metabolismo , Inmunosupresores/farmacocinética , Hígado/inmunología , Orosomucoide/metabolismo , Receptores de Superficie Celular/metabolismo , Tacrolimus/farmacocinética , Administración Oral , Animales , Receptor de Asialoglicoproteína , Proteínas Portadoras/sangre , Proteínas Portadoras/aislamiento & purificación , Proteínas Portadoras/metabolismo , Células Cultivadas , Proteínas de Unión al ADN/sangre , Proteínas de Unión al ADN/aislamiento & purificación , Proteínas de Unión al ADN/metabolismo , Citometría de Flujo , Proteínas de Choque Térmico/sangre , Proteínas de Choque Térmico/aislamiento & purificación , Proteínas de Choque Térmico/metabolismo , Humanos , Inmunosupresores/administración & dosificación , Hígado/metabolismo , Ratas , Tacrolimus/administración & dosificación , Proteínas de Unión a Tacrolimus , Distribución TisularAsunto(s)
Fibromatosis Agresiva/cirugía , Mucosa Intestinal/trasplante , Intestino Delgado/trasplante , Proteínas de Neoplasias , Complicaciones Posoperatorias , Neoplasias Retroperitoneales/cirugía , Proteínas Supresoras de Tumor , Neoplasias Vasculares/cirugía , Adulto , Biomarcadores/sangre , Proteínas Portadoras/sangre , Citocinas/sangre , Proteína de Unión a los Ácidos Grasos 7 , Proteínas de Unión a Ácidos Grasos , Ácidos Grasos , Humanos , Inflamación , Mucosa Intestinal/patología , Mucosa Intestinal/fisiología , Intestino Delgado/patología , Intestino Delgado/fisiología , Donadores Vivos , Masculino , Arteria Mesentérica Superior , Venas Mesentéricas , Proteína P2 de Mielina/sangre , Recurrencia Local de Neoplasia , Síndrome , Gemelos MonocigóticosRESUMEN
In a case of human syngeneic intestinal transplantation, the post-operative course was complicated by the Systemic Inflammatory Response System (SIRS). This syndrome was characterized by negative cultures and elevated levels of the pro-inflammatory cytokines, IL-1 beta, IL-6 and TNF. In keeping with current concepts of translocation across the enterocyte barrier as the etiology of SIRS, levels of intestinal fatty acid binding protein (I-FABP), an enterocyte-specific protein, also increased. These observations suggest that (i) a clinical syndrome consistent with translocation may occur in the absence of rejection in intestinal transplantation, and (ii) I-FABP may serve as a clinically relevant marker for enterocyte injury.
Asunto(s)
Proteínas Portadoras/sangre , Ciego/trasplante , Enteritis/diagnóstico , Ácidos Grasos/metabolismo , Íleon/trasplante , Intestinos/citología , Proteína P2 de Mielina/sangre , Proteínas de Neoplasias , Proteínas Supresoras de Tumor , Adulto , Biomarcadores/sangre , Supervivencia Celular , Citocinas/sangre , Enteritis/etiología , Células Epiteliales , Proteína de Unión a los Ácidos Grasos 7 , Proteínas de Unión a Ácidos Grasos , Humanos , Masculino , Complicaciones Posoperatorias , Trasplante IsogénicoRESUMEN
Invasive pulmonary aspergillosis (IPA) is often a lethal entity in transplant recipients (up to 90%). We report the successful treatment of a case of IPA in a renal transplant recipient whose only risk for exposure was habitual marijuana smoking. Although marijuana smoking has been linked to the development of IPA in patients immunosuppressed for a variety of reasons, this case is the first report involving a solid organ transplant recipient. The patient's clinical course and treatment are described and the literature is reviewed with respect to environmental and patient risk factors. In this case, IPA was associated with the patient's heavy usage of marijuana during the immediate posttransplant period. Treatment was successful and included the experimental amphotericin product amphotericin B colloidal dispersion. Contemporaneous exposure to a large amount of inocula of Aspergillus within 30 days of receiving high doses of steroids appeared to be the most important factor that predisposed this patient to IPA. Transplant recipients should be specifically proscribed from marijuana use during periods of high steroid administration.
Asunto(s)
Antifúngicos/uso terapéutico , Aspergilosis/tratamiento farmacológico , Aspergilosis/etiología , Itraconazol/uso terapéutico , Trasplante de Riñón/efectos adversos , Enfermedades Pulmonares Fúngicas/tratamiento farmacológico , Enfermedades Pulmonares Fúngicas/etiología , Fumar Marihuana/efectos adversos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Factores de RiesgoRESUMEN
We hypothesized that, following experimental small bowel transplantation, immunosuppressive therapy initiated on the day of the initial rise in serum intestinal fatty acid-binding protein (I-FABP) would result in graft salvage. In previously published work, we showed that I-FABP was not detectable in the serum of isografted Lewis rats, but could be measured in the peripheral circulation during small bowel allograft rejection. A clinically useful method to monitor trans- planted allografts for rejection should detect the problem early in its evolution so that treatment to reverse the process would salvage a functional organ. Lewis rats served as recipients of LBNF1 out-of-continuity small bowel allografts and were studied in two groups: group I (control) received no immunosuppression and group II received cyclosporine (CsA, 15 mg/kg/d, p.o.) when I-FABP rose to > or = 80 ng/ml. Serum I-FABP was measured daily until the time of sacrifice. Full-thickness graft biopsies were obtained on postoperative days 3 (baseline), 6 or 7 (elevated I-FABP), 10, and 14 (sacrifice). Following transplantation baseline serum I-FABP (day 2 or 3) averaged < or = 10.0 ng/ml. I-FABP remained at baseline through day 5 (range 0-50 ng/ml) in all animals and then rose abruptly on either day 6 or 7 (range 86-150 ng/ml; P < 0.001 vs. baseline). Histology on day 6 or 7 revealed a mild-to-moderate cellular rejection. Cyclosporine therapy reversed the rejection reaction and restored the bowel to normal histology. Serum I-FABP returned to baseline. In untreated animals, serum I-FABP remained elevated for several days and then returned to baseline levels coincident with fulminant rejection and mucosal sloughing. I-FABP was released into the peripheral circulation early in the evolution of acute rejection in this model of small bowel transplantation. Immunosuppressive therapy initiated when elevated levels of I-FABP were detected in the serum resulted in graft salvage. Cyclosporine immunotherapy consistently reversed rejection in this model. This article represents the first report of salvage of small bowel allografts when immunosuppressive therapy was instituted prospectively on the basis of a serum marker. Immunoreactive I-FABP appears to hold significant potential as a biochemical screening tool for acute rejection occurring In small bowell allografts.